You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Mobocertinib succinate - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic sources for mobocertinib succinate and what is the scope of patent protection?

Mobocertinib succinate is the generic ingredient in one branded drug marketed by Takeda Pharms Usa and is included in one NDA. There are two patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Mobocertinib succinate has sixty-one patent family members in thirty-nine countries.

One supplier is listed for this compound.

Summary for mobocertinib succinate
International Patents:61
US Patents:2
Tradenames:1
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Raw Ingredient (Bulk) Api Vendors: 12
DailyMed Link:mobocertinib succinate at DailyMed
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for mobocertinib succinate
Generic Entry Date for mobocertinib succinate*:
Constraining patent/regulatory exclusivity:
Dosage:
CAPSULE;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for mobocertinib succinate

US Patents and Regulatory Information for mobocertinib succinate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Takeda Pharms Usa EXKIVITY mobocertinib succinate CAPSULE;ORAL 215310-001 Sep 15, 2021 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Takeda Pharms Usa EXKIVITY mobocertinib succinate CAPSULE;ORAL 215310-001 Sep 15, 2021 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y Y ⤷  Try a Trial
Takeda Pharms Usa EXKIVITY mobocertinib succinate CAPSULE;ORAL 215310-001 Sep 15, 2021 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Takeda Pharms Usa EXKIVITY mobocertinib succinate CAPSULE;ORAL 215310-001 Sep 15, 2021 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y Y ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for mobocertinib succinate

Country Patent Number Title Estimated Expiration
Georgia, Republic of P20207111 Heteroaryl compounds for kinase inhibition ⤷  Try a Trial
European Patent Office 3778584 PROCÉDÉ DE PRÉPARATION DE DÉRIVÉS DE 2-CHLORO-4-HÉTÉROARYL-PYRIDIMIDINES (PRODUCTION PROCESS OF 2-CHLORO-4-HETEROARYL-PYRIMIDINE DERIVATIVES) ⤷  Try a Trial
Mexico 2016016766 COMPUESTOS DE HETEROARILO PARA LA INHIBICION DE CINASA. (HETEROARYL COMPOUNDS FOR KINASE INHIBITION.) ⤷  Try a Trial
Georgia, Republic of AP202014706 Heteroaryl compounds for kinase inhibition ⤷  Try a Trial
Ecuador SP17003553 COMPUESTOS DE HETEROARILO PARA LA INHIBICIÓN DE CINASA ⤷  Try a Trial
South Africa 201608224 HETEROARYL COMPOUNDS FOR KINASE INHIBITION ⤷  Try a Trial
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for mobocertinib succinate

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
3157916 C03157916/01 Switzerland ⤷  Try a Trial PRODUCT NAME: MOBOCERTINIB; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 68147 01.06.2022
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.